Menu
PacPremier
Magic Hour
Montecito
Loading...
You are here:  Home  >  'Amgen'  -  Page 60
Latest

Amgen shares jump on good news from melanoma drug study

By   /  Wednesday, March 20th, 2013  /  Latest news  /  Comments Off on Amgen shares jump on good news from melanoma drug study

[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”20-09-2012″ enddate=”20-03-2013″ width=”300″ height=”245″] Shares of Thousand Oaks-based Amgen rose in light trading on March 20 after the company announced favorable results from a drug that treats advanced melanoma. The drug, dubbed T-VEC, uses a virus to infiltrate tumors and shrink them. It achieved positive results in a large number Read More →

Read More →
Latest

Amgen loses case before U.S. Supreme Court

By   /  Wednesday, February 27th, 2013  /  Latest news, Law  /  Comments Off on Amgen loses case before U.S. Supreme Court

Thousand Oaks-based Amgen has lost a case before the U.S. Supreme Court that would have made it much more difficult for shareholders of public companies to band together and sue firms when their leaders make false or misleading statements. In Amgen v. Connecticut Retirement Plans and Trust Funds, the biotech giant sought to tighten the Read More →

Read More →
Latest

Amgen inks $180M nanomedicine deal

By   /  Tuesday, January 8th, 2013  /  Banking & Finance, Latest news, Tri-County Public Companies  /  Comments Off on Amgen inks $180M nanomedicine deal

Thousand Oaks-based Amgen has entered a deal to pay up to $180.5 million for nanomedicine tumor treatments being developed by a Massachusetts company. Cambridge-based Bind Biosciences said it has entered a development agreement with Amgen for its kinase inhibitor nanomedicines for treating a range of solid tumors. The medicines are highly targeted and can be Read More →

Read More →
Latest

Amgen to pay $150M for misbranding Aranesp

By   /  Tuesday, December 18th, 2012  /  Latest news  /  Comments Off on Amgen to pay $150M for misbranding Aranesp

[Editor’s note: This story has been updated with comments from Amgen.] Biotech giant Amgen pleaded guilty Dec. 18 to a misdemeanor charge for misbranding its anemia drug Aranesp. According to a report from Bloomberg News, the Thousand Oaks-based firm agreed to pay $150 million in fines and penalties as part of the guilty plea. U.S. Read More →

Read More →
Latest

Amgen buys DeCode Genetics for $415M

By   /  Monday, December 10th, 2012  /  Banking & Finance, Latest news, Technology, Tri-County Public Companies  /  Comments Off on Amgen buys DeCode Genetics for $415M

Biotech giant Amgen is buying Icelandic genetics research firm DeCode Genetics for $415 million, the Thousand Oaks company said Dec. 10. The all-cash deal is expected to close before the end of the year and will give Amgen, the largest biotechnology firm in the world, opportunities to develop new medicines that target defective DNA. “DeCode Read More →

Read More →
Latest

Amgen Tour to hit Santa Barbara, Avila Beach

By   /  Tuesday, November 27th, 2012  /  Latest news, Tourism  /  Comments Off on Amgen Tour to hit Santa Barbara, Avila Beach

[Editor’s note: This story has been updated with additional information.] The Amgen Tour of California will return to Santa Barbara and visit Avila Beach for the first time ever when the Tri-Counties hosts the end of Stage 4 and all of Stage 5 for the eight-year-old road cycle racing event next year. AEG, presenter of Read More →

Read More →
Latest

Amgen aims to put cholesterol drug on market

By   /  Monday, November 19th, 2012  /  Banking & Finance, Technology, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen aims to put cholesterol drug on market

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →